12.4 Cardiovascular Pharmacotherapy: Nitroglycerin, ASA & Epinephrine

12.4 Cardiovascular Pharmacotherapy: Nitroglycerin, ASA & Epinephrine

Pharmacological Foundations: Adrenergic, Nitrate & Antiplatelet Pathways

Primary care paramedics routinely administer targeted cardiovascular pharmacotherapy to alter intravascular hemodynamics, inhibit thrombogenesis, and stimulate adrenergic receptor pathways (CPCF Appendix A #5, #32). Mastering the receptor kinetics, cellular mechanisms, contraindications, and potential toxicities of Acetylsalicylic Acid (ASA), Nitroglycerin, and Epinephrine is essential for clinical competence and paramedic licensure in Canada.

---

Acetylsalicylic Acid (ASA): Mechanism, Antiplatelet Kinetics & Dosing

Acetylsalicylic acid (aspirin) is an irreversible antiplatelet agent that forms the absolute cornerstone of early medical management in suspected Acute Coronary Syndrome (ACS).

Cellular Mechanism of Action

Platelet activation at the site of a ruptured atheromatous plaque generates arachidonic acid from platelet membrane phospholipids via phospholipase A2. Intracellular cyclooxygenase-1 (COX-1) converts arachidonic acid into prostaglandin H2 ($PGH_2$), which is subsequently isomerized by thromboxane synthase into Thromboxane A2 (TXA2). TXA2 is a potent platelet agonist and vasoconstrictor that promotes platelet degranulation, shape change, and activation of glycoprotein IIb/IIIa receptors, driving rapid thrombus propagation.

• Irreversible Acetylation: ASA covalently acetylates a serine residue (Ser-529) in the active catalytic channel of platelet COX-1, permanently blocking substrate access. Because platelets are anucleate cell fragments lacking ribosomal machinery, they cannot synthesize replacement COX-1 proteins. Platelet COX-1 remains inactivated for the entire circulating lifespan of the platelet (7 to 10 days).
• Clinical Dosing & Administration: 160 mg to 325 mg (in Canada, standard prehospital administration is two 80 mg or 81 mg chewable pediatric tablets = 160–162 mg).
• Chewable Formulation: Tablets must be chewed thoroughly before swallowing. Chewing pulverizes the formulation and enables rapid direct absorption across the rich vascular network of the buccal and sublingual mucosa, achieving therapeutic antiplatelet action within 15 to 20 minutes. Swallowing enteric-coated whole tablets delays therapeutic onset for up to 2 to 4 hours due to slow gastric emptying.

Indications & Strict Contraindications

• Indications: All patients with suspected ischemic chest pain or anginal equivalents suggestive of Acute Coronary Syndrome.
• Absolute Contraindications:
  1. True anaphylactic hypersensitivity to ASA, salicylates, or non-steroidal anti-inflammatory drugs (NSAIDs) (manifesting as bronchospasm, urticaria, or angioedema).
  2. Active, gross gastrointestinal hemorrhage (e.g., active hematemesis, melena) or severe acute bleeding diathesis.
• Clarifying Daily Aspirin Regimens: A patient who takes daily baby aspirin (81 mg) has partial platelet suppression. Paramedics must administer the full prehospital loading dose (160–162 mg chewable) to ensure complete blockade of all newly released circulating platelets.

---

Sublingual Nitroglycerin: Hemodynamics, Preload Reduction & Administration

Nitroglycerin (glyceryl trinitrate [GTN]) is an organic nitrate that acts as a potent vascular smooth muscle relaxant and vasodilator.

Mechanism of Action & Intracellular Cascade

1. Conversion to Nitric Oxide: Nitroglycerin enters vascular endothelial and smooth muscle cells, where it is bio-transformed by mitochondrial aldehyde dehydrogenase-2 (ALDH-2) into active nitric oxide (NO).
2. Activation of Guanylyl Cyclase: Nitric oxide stimulates soluble guanylyl cyclase (sGC), which catalyzes the intracellular conversion of guanosine triphosphate (GTP) into cyclic guanosine monophosphate (cGMP).
3. Dephosphorylation of Myosin: Elevated cGMP activates protein kinase G (PKG), which promotes intracellular calcium extrusion and dephosphorylates myosin light chains, inducing profound vascular smooth muscle relaxation.

Hemodynamic Effects

• Venodilation (Predominant Effect): At standard prehospital sublingual doses, nitroglycerin acts primarily as a venodilator. It dramatically expands capacitance in the systemic venous system, pooling blood in peripheral and splanchnic vascular beds. This reduces venous return to the right heart, lowering Left Ventricular End-Diastolic Pressure (preload) and reducing left ventricular wall tension. By Laplace's law ($T = P \times r / 2h$), diminished wall tension directly curtails myocardial oxygen demand ($MVO_2$).
• Coronary Vasodilation: Relieves dynamic coronary vasospasm, improves collateral coronary perfusion, and redistributes blood flow toward ischemic subendocardial layers.
• Arteriolar Dilation (Higher Doses): Produces modest reduction in systemic vascular resistance, decreasing left ventricular afterload.

Clinical Administration Parameters

• Formulation: 0.4 mg (400 mcg) per metered sublingual spray or sublingual tablet.
• Frequency: 1 dose every 5 minutes, up to a maximum of 3 doses, provided vital signs remain within safe parameters.
• Mandatory Reassessment: Paramedics must reassess blood pressure and heart rate immediately before each dose.

---

Nitroglycerin Contraindications: PDE-5 Inhibitors & Right Ventricular Infarction

Nitroglycerin is a potent vasoactive medication with strict physiological and pharmacological contraindications:

Absolute Contraindications to Prehospital Nitroglycerin:
1. Systolic Blood Pressure <90–100 mmHg (or >30 mmHg drop below baseline)
2. Heart rate outside the range set by the local medical directive
   (commonly bradycardia below 50-60 bpm or tachycardia above 100-160 bpm;
   Canadian provincial directives differ, so know your own)
3. Right Ventricular Myocardial Infarction (ST elevation in lead V4R)
4. Recent Use of Phosphodiesterase Type 5 (PDE-5) Inhibitors:
   - Sildenafil (Viagra, Revatio) within 24 hours
   - Vardenafil (Levitra) within 24 hours
   - Tadalafil (Cialis, Adcirca) within 48 hours

The Lethal PDE-5 Inhibitor Interaction

Phosphodiesterase type 5 (PDE-5) is the primary intracellular enzyme responsible for breaking down cGMP into inactive 5'-GMP. Medications such as sildenafil, vardenafil, and tadalafil are competitive PDE-5 inhibitors prescribed for erectile dysfunction and pulmonary arterial hypertension:

• Synergistic cGMP Accumulation: Nitroglycerin dramatically increases cGMP synthesis, while PDE-5 inhibitors simultaneously block cGMP breakdown. When co-administered, cGMP concentrations inside vascular smooth muscle skyrocket to massive levels.
• Refractory Hemodynamic Collapse: This triggers uninhibited, systemic arteriolar and venular vasodilation. Systemic vascular resistance drops precipitously, producing severe, irreversible hypotension, complete loss of coronary perfusion pressure, and fatal cardiovascular collapse refractory to aggressive fluid resuscitation.
• Time Windows: Sildenafil and vardenafil possess elimination half-lives of approximately 4 hours, establishing an absolute contraindication window of 24 hours. Tadalafil has an extended elimination half-life (~17.5 hours), dictating an absolute contraindication window of at least 48 hours.

---

Epinephrine in Cardiac Arrest: Alpha-1 Vasoconstriction & Perfusion Pressures

Epinephrine (adrenaline) is an endogenous catecholamine that non-selectively stimulates alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors. In cardiac arrest resuscitation, it serves as the primary vasopressor.

Mechanism of Action in Pulseless Arrest

During cardiopulmonary resuscitation, forward blood flow is minimal (~20%–30% of baseline). The therapeutic objective of epinephrine in cardiac arrest is NOT cardiac stimulation (beta-1 agonism), but rather potent peripheral vasoconstriction mediated by alpha-1 adrenergic receptors:

• Alpha-1 Peripheral Vasoconstriction: Epinephrine binds alpha-1 receptors on vascular smooth muscle, activating the Gq-phospholipase C pathway to increase intracellular calcium. This intensely constricts non-essential peripheral arterial beds (skin, skeletal muscle, splanchnic circulation, renal vasculature).
• Elevating Aortic Diastolic Pressure: Massive peripheral vasoconstriction prevents blood runoff into distal capillary beds, elevating aortic root diastolic pressure during the decompression phase of CPR.
• Augmenting Coronary & Cerebral Perfusion: As aortic diastolic pressure rises, the pressure gradient driving blood flow into the coronary arteries (Coronary Perfusion Pressure [CPP]) and cerebral circulation increases significantly, promoting myocardial recovery and the return of organized electrical activity.

Clinical Administration in Adult Resuscitation

• Formulation & Concentration: 1 mg of 1:10,000 (0.1 mg/mL) administered intravenously (IV) or intraosseously (IO).
• Flush Protocol: Follow each 1 mg dose with an immediate 20 mL normal saline flush and elevate the patient's extremity for 10 to 20 seconds to rapidly propel the medication from peripheral veins into the central circulation.
• Timing & Rhythms:
  • Non-Shockable Rhythms (Asystole / PEA): Administer as soon as vascular access is established. Early epinephrine administration in non-shockable arrest correlates strongly with higher ROSC rates.
  • Shockable Rhythms (VF / pulseless VT): Administer after the second shock (during the 3rd CPR cycle), repeated every 3 to 5 minutes thereafter. Initial efforts in shockable rhythms prioritize immediate defibrillation and CPR before pharmacotherapy.

---

Epinephrine in Severe Anaphylaxis: Intramuscular Mechanics & Route Safety

In severe acute anaphylaxis, massive systemic mast cell and basophil degranulation releases histamine, leukotrienes, and platelet-activating factor, triggering catastrophic bronchospasm, mucosal angioedema, and distributive shock.

Receptor Mechanics in Anaphylaxis

• Alpha-1 Agonism: Reverses profound peripheral vasodilation, restores systemic vascular resistance, and curtails microvascular capillary leakage, relieving life-threatening laryngeal angioedema.
• Beta-2 Agonism: Relaxes bronchial smooth muscle via adenylate cyclase stimulation (increasing cyclic AMP), reversing acute bronchospasm; simultaneously binds beta-2 receptors on mast cells, halting further release of inflammatory mediators.
• Beta-1 Agonism: Enhances cardiac inotropy and chronotropy to support cardiac output in distributive shock.

Dosing & Administration: The Anterolateral Thigh (Vastus Lateralis)

• Concentration: 1:1,000 (1.0 mg/mL).
• Adult Dose: 0.3 mg to 0.5 mg (0.3–0.5 mL of 1:1,000) administered strictly Intramuscularly (IM).
• Pediatric Dose: 0.01 mg/kg IM (maximum single dose 0.3 mg).
• Anatomical Site: The anterolateral mid-thigh (vastus lateralis) is the mandatory injection site. Pharmacokinetic studies prove that the extensive vascularity of the vastus lateralis achieves peak plasma epinephrine concentrations within 8 minutes—more than three times faster than injection into the deltoid muscle or subcutaneous adipose tissue.

[!CAUTION] The Lethal Error of IV 1:1,000 Epinephrine: Administering the concentrated 1:1,000 (1 mg/mL) formulation intravenously to a non-arrest patient is a lethal medication error. A rapid IV bolus of concentrated epinephrine triggers extreme hypertension, intracranial hemorrhage, acute myocardial infarction, and fatal ventricular tachyarrhythmias. IV epinephrine is reserved strictly for cardiac arrest (using the dilute 1:10,000 formulation) or highly specialized, micro-dose IV infusions titrated by advanced life support clinicians.

---

Comprehensive Cardiovascular Pharmacotherapy Comparison

---

Clinical Scenario: ACS with a Hidden PDE-5 Inhibitor Interaction

A 58-year-old male calls 911 for sudden, crushing retrosternal chest pain radiating to both shoulders, accompanied by nausea and diaphoresis, which started 1 hour ago while gardening. Vital signs: BP 142/88 mmHg, HR 78 bpm regular, RR 18/min, SpO2 98% on room air.

1. Diagnostic Assessment: Paramedics obtain a 12-lead ECG within 7 minutes, demonstrating 2 mm ST elevation in leads V2 through V5 (acute anterior STEMI). STEMI bypass protocol is activated.
2. Pharmacological Screening: The crew prepares to administer standard ACS medications. When asked about medication allergies and current prescriptions, the patient initially denies taking any medications.
3. Targeted Medication Inquiry: Recognizing the severe risks of organic nitrates, the paramedic asks specifically: 'Have you taken any medications for erectile dysfunction, prostate issues, or pulmonary hypertension in the past two days, such as Viagra or Cialis?' The patient hesitates and admits to taking a tadalafil (Cialis) 20 mg tablet 32 hours ago.
4. Therapeutic Adjustment:
   • ASA: Paramedics immediately administer 162 mg of chewable ASA, which the patient chews and swallows. ASA has zero adverse hemodynamic interaction with PDE-5 inhibitors.
   • Nitroglycerin: The crew strictly withholds all nitroglycerin. Although 32 hours have passed, tadalafil's long elimination half-life mandates an absolute contraindication window of 48 hours. Administering nitroglycerin would precipitate catastrophic, fatal hypotension.
   • Pain Management: Alternative non-nitrate analgesia is coordinated with online medical direction, and the patient is transported without hemodynamic compromise directly to the catheterization laboratory.

---

Exam Pitfalls & High-Yield Pharmacotherapy Pearls

• Withholding ASA for Daily Baby Aspirin Users: Never withhold prehospital chewable ASA because the patient takes 81 mg daily; provide the full 160–162 mg loading dose.
• Missing Tadalafil's 48-Hour Window: Remembering that sildenafil is 24 hours but missing that tadalafil requires a full 48-hour washout is a frequent licensing exam trap.
• Administering Nitroglycerin Outside the Permitted Heart-Rate Range: Nitroglycerin is withheld when the heart rate falls outside the range set by the local medical directive, because venodilation in an already tachycardic or bradycardic patient worsens myocardial ischemia. The exact cut-offs differ between Canadian provincial directives (commonly bradycardia below 50–60 bpm, tachycardia above 100–160 bpm), so answer the national principle on the examination and the local number on the road.
• Route Errors with Epinephrine: Never administer 1:1,000 epinephrine via the intravenous route in anaphylaxis; it must be administered intramuscularly into the anterolateral thigh (vastus lateralis).